Sarepta stock soars as early-stage gene therapy data shows promise

(Reuters) - Sarepta Therapeutics Inc reported promising results on Tuesday from an early-stage study testing its gene therapy in patients with Duchenne muscular dystrophy (DMD), driving the company's shares up 60 percent.

Sarepta said data from the three-patient study showed an 87 percent mean reduction in serum creatine kinase levels, which is used as a preliminary diagnosis tool for DMD.

(Reporting by Manas Mishra in Bengaluru; Editing by Sai Sachin Ravikumar)

See Also:

• UK still plans to end sale of new diesel and petrol cars by 2040: source

• Hungary to levy tax on aid groups supporting immigrants

• Turkish court acquits rapper arrested over lyrics: CNN Turk